Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Guggenheim

Guggenheim assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note published on Monday, Marketbeat.com reports. The firm issued a buy rating and a $50.00 price target on the stock.

Several other brokerages have also recently weighed in on AVTX. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, January 15th. Finally, Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.88.

Avalo Therapeutics Stock Up 3.6%

Avalo Therapeutics stock opened at $15.65 on Monday. The company has a fifty day simple moving average of $17.36 and a 200-day simple moving average of $14.00. The firm has a market capitalization of $289.68 million, a price-to-earnings ratio of -2.92 and a beta of 0.88. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). On average, research analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently modified their holdings of AVTX. Geode Capital Management LLC increased its position in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares during the last quarter. Quadrature Capital Ltd purchased a new position in Avalo Therapeutics during the second quarter worth about $55,000. Velan Capital Investment Management LP boosted its stake in Avalo Therapeutics by 38.4% during the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after buying an additional 43,000 shares during the period. Nantahala Capital Management LLC increased its position in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after acquiring an additional 95,000 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after acquiring an additional 400,898 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.